UCHL5 and chronic myelogenous leukemia, BCR-ABL1 positive: We demonstrated that targeting USP14 and UCHL5 by b‐AP15 showed obvious antitumour efficiency in BCR‐ABLWT and BCR‐ABLT315I CML cell lines and xenografts, as well as in primary CML cells.